[1]冯超,徐冲,阎静,等.玻璃体内注射雷珠单抗治疗重度非增生型糖尿病视网膜病变伴黄斑水肿后患者脉络膜厚度的变化[J].眼科新进展,2017,37(4):335-337.[doi:10.13389/j.cnki.rao.2017.0084]
　FENG Chao,XU Chong,YAN Jing,et al.Changes of choroidal thickness after ranibizumab treatment for non-proliferative diabetic retinopathy with macular edema[J].Recent Advances in Ophthalmology,2017,37(4):335-337.[doi:10.13389/j.cnki.rao.2017.0084]
点击复制

玻璃体内注射雷珠单抗治疗重度非增生型糖尿病视网膜病变伴黄斑水肿后患者脉络膜厚度的变化/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
37卷
期数:
2017年4期
页码:
335-337
栏目:
应用研究
出版日期:
2017-04-05

文章信息/Info

Title:
Changes of choroidal thickness after ranibizumab treatment for non-proliferative diabetic retinopathy with macular edema
作者:
冯超; 徐冲; 阎静; 吴建华
430064　湖北省武汉市，武汉爱尔眼科医院
Author(s):
FENG Chao; XU Chong; YAN Jing; WU Jian-Hua
Wuhan Aier Eye Hospital，Wuhan 430064，Hubei Province，China
关键词:
非增生型糖尿病视网膜病变; 黄斑水肿; 脉络膜厚度
Keywords:
non-proliferative diabetic retinopathy; macular edema; choroidal thickness
分类号:
R773.4
DOI:
10.13389/j.cnki.rao.2017.0084
文献标志码:
A
摘要:
目的　观察玻璃体内注射雷珠单抗治疗重度非增生型糖尿病视网膜病变伴黄斑水肿后患者脉络膜厚度的变化情况，明确脉络膜厚度与患者视力之间的相关性。方法　选取在我院确诊为重度非增生型糖尿病视网膜病变伴黄斑水肿患者23例(23眼)，每月眼内注射1次雷珠单抗并连续接受3次治疗，记录患者治疗前以及治疗后1个月、2个月、3个月黄斑中心凹下脉络膜厚度，同时记录患者黄斑区视网膜神经上皮厚度和最佳矫正视力。分析黄斑中心凹下脉络膜厚度、黄斑区视网膜神经上皮厚度、最佳矫正视力的动态变化情况以及相关性。结果　玻璃体内注射雷珠单抗后1个月、2个月、3个月黄斑中心凹下脉络膜厚度和黄斑区视网膜神经上皮厚度均连续下降，前两个月与治疗前相比两指标差异均无统计学意义（均为P>0.05），第3个月时与治疗前相比，差异均有统计学意义(P=0.04、0.01)。最佳矫正视力在治疗过程中持续得到改善，前两个月与治疗前相比差异均无统计学意义（均为P>0.05），第3个月时与治疗前相比，差异有统计学意义(P=0.04)。治疗前黄斑中心凹下脉络膜厚度与黄斑区视网膜神经上皮厚度之间存在正相关性(R2=0.94，P=0.00)；与治疗前和治疗后3个月最佳矫正视力之间均存在正相关性(R2=0.93，P=0.00；R2=0.82，P=0.00)。治疗前黄斑区视网膜神经上皮厚度与治疗后3个月最佳矫正视力之间也存在正相关性(R2=0.83，P=0.00)。治疗前最佳矫正视力与治疗后3个月最佳矫正视力之间同样存在正相关性(R2=0.84，P=0.00)。结论　黄斑中心凹下脉络膜厚度可以作为评价重度非增生型糖尿病视网膜病变伴黄斑水肿病情变化的有效临床指标，而且可以一定程度上预测抗血管内皮生长因子治疗的效果。
Abstract:
Objective　To observe the changes of choroidal thickness after ranibizumab treatment for non-proliferative diabetic retinopathy (NPDR) with macular edema,and determine the association between choroidal thickness and visual acuity.Methods　Twenty-three eyes from 23 patients diagnosed with NPDR and diabetic macular edema were treated with 3 monthly intravitreal injections of ranibizumab.The subfoveal choroidal thickness and central macular thickness were measured,and the best corrected visual acuity was recorded.Changes of subfoveal choroidal thickness,correlation between subfoveal choroidal thickness and best corrected visual acuity were assessed at 3 months follow-up.Results　After 3 monthly anti-VEGF treatments,subfoveal choroidal thickness and central macular thickness decreased significantly,there was no statistical difference at 1 month and 2 months compared with pre-treatment (all P>0.05),but there was statistical differences at 3 months compared with pre-treatment (P=0.04,0.01).In the treatment,the best corrected visual acuity increased gradually,there was no statistical difference at 1 month and 2 months compared with pre-treatment (all P>0.05),but there was statistical differences at 3 months compared with pre-treatment (P=0.04).Before the treatment,the subfoveal choroidal thickness was positive correlated with macular retinal thickness (R2=0.94,P=0.00);And the best corrected visual acuity before treatment and 3 months after treatment had a positive correlation (R2=0.93,P=0.00;R2=0.82,P=0.00).There was a positive correlation between central macular thickness and best corrected visual acuity at 3 months after treatment (R2=0.83,P=0.00).There was a positive correlation in the best corrected visual acuity between before treatment and 3 months after treatment (R2=0.84,P=0.00).Conclusion　The subfoveal choroidal thickness is a clinical index to evaluate the efficacy of anti-VEGF in the treatment of diabetic macular edema.Baseline subfoveal choroidal thickness can be considered as one of the indicators of clinical efficacy in the short term.

参考文献/References:

［1］　ROMERO-AROCA P.Managing diabetic macular edema：the leading cause of diabetes blindness［J］.World J Diabetes，2011，2 (6)：98-104.
［2］　QUERQUES G，LATTANZIO R，QUERQUES L，DEL TURCO C，FORTE R，PIERRO L，et al.Enhanced depth imaging optical coherence tomography in type 2 diabetes［J］.Invest Ophthalmol Vis Sci，2012，53(10)：6017-6024.
［3］　SPAIDE RF，KOIZUMI H，POZZONI MC.Enhanced depth imaging spectral-domain optical coherence tomography［J］.Am J Ophthalmol，2008，146(4)：496-500.
［4］　MARGOLIS R，SPAIDE RF.A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes［J］.Am J Ophthalmol，2009，147(5)：811-815.
［5］　FUJIWARA T，IMAMURA Y，MARGOLIS R，SLAKTER JS，SPAIDE RF.Enhanced depth imaging optical coherence tomography of the choroid in highly myopic eyes［J］.Am J Ophthalmol，2009，148(3)：445-450.
［6］　IMAMURA Y，FUJIWARA T，MARGOLIS R，SPAIDE RF.Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy［J］.Retina，2009，29(10)：1469-1473.
［7］　CHUNG SE，KANG SW，LEE JH，KIM YT.Choroidal thickness in polypoidal choroidal vasculopathy and exudative agerelated macular degeneration［J］.Ophthalmology，2011，118(5)：840-845.
［8］　KIM SW，OH J，KWON SS，YOO J，HUH K.Comparison of choroidal thickness among patients with healthy eyes，early age-related maculopathy，neovascular age-related macular degeneration，central serous chorioretinopathy，and polypoidal choroidal vasculopathy［J］.Retina，2011，31(9)：1904-1911.
［9］　FLORES-MORENO I，RUIZ-MEDRANO J，DUKER JS，RUIZ-MORENO JM.The relationship between retinal and choroidal thickness and visual acuity in highly myopic eyes［J］.Br J Ophthalmol，2013，97(8)：1010-1013.
［10］　LEHMANN M，WOLFF B，VASSEUR V，MARTINET V，MANASSEH N，SAHEL JA，et al.Retinal and choroidal changes observed with en face enhanced-depth imaging OCT in central serous chorioretinopathy［J］.Br J Ophthalmol，2013，97(9)：1181-1186.
［11］　DHOOT DS，HUO S，YUAN A，XU D，SRIVISTAVA S，EHLERS JP，et al.Evaluation of choroidal thickness in retinitis pigmentosa using enhanced depth imaging optical coherence tomography［J］.Br J Ophthalmol，2013，97(1)：66-69.
［12］　许迅，郑颖.重视对糖尿病黄斑水肿的治疗［J］.中华眼底病杂志，2016，32(2)：119-121.
XU X，ZHENG Y.Focusing on the treatment of diabetic macular edema［J］.Chin J Ocul Fundus Dis，2016，32(2)：119-121.
［13］　MASSIN P，BANDELLO F，GARWEG JG，HANSEN LL，HARDING SP，LARSEN M，et al.Safety and efficacy of ranibizumab in diabetic macular edema (RESLOVE)：a 12 month randomized，controlled，double_masked，muhicenter phaseⅡstudy［J］.Diabetes Care，2010，33(11)：2399-2405.
［14］　NICKLA DL，WALLMAN J.The multifunctional choroid［J］.Prog Retin Eye Res，2010，29(2)：144-168.
［15］　ADHI M，BREWER E，WAHEED NK，DUKER JS.Analysis of morphological features and vascular layers of choroid in diabetic retinopathy using spectral domain optical coherence to-mography［J］.JAMA Ophthalmol，2013，131(10)：1267-1274.
［16］　REGATIERI CV，BRANCHINI L，CARMODY J，FUJIMOTO JG，DUKER JS.Choroidal thickness in patients with diabetic reti-nopathy analyzed by spectral-domain optical coherence to-mography［J］.Retina，2012，32(3)：563-568.
［17］　刘轩，谢安明.内皮抑素对小鼠脉络膜新生血管抑制作用的信号通路分析［J］.新乡医学院学报，2014，31(4)：260-263.
LIU X，XIE AM.Analysis of signaling pathway of inhibitory effect of endostatin on mouse choroidal neovascularization［J］.J Xinxiang Med Univ，2014，31(4)：260-263.
［18］　LUTTY GA，CAO J，MCLEOD DS.Relationship of polymorpho-nuclear leukocytes to capillary dropout in the human diabetic choroid［J］.Am J Pathol，1997，151(3)：707-714.
［19］　MORI F，HIKICHI T，TAKAHASHI J，NAGAOKA T，YOSHIDA A.Dysfunction of active transport of blood-retinal barrier in pa-tients with clinically significant macular edema in type 2 diabetes［J］.Diabetes Care，2002，25(7)：1248-1249.
［20］　VINORES SA，YOUSSRI AI，LUNA JD，CHEN YS，BHARGAVE S，VINORES MA，et al.Upregulation of vascular endothelial growth factor in ischemic and nonischemic human and experimental retinal disease［J］.Histol Histopathol，1997，12(1)：99-109.
［21］　AIELLO LP，NORTHRUP JM，KEYT BA，TAKAGI H，IWAMOTO MA.Hypoxic regulation of vascular endothelial growth factor in retinal cells［J］.Arch Ophthalmol，1995，113(12)：1538-1544.

相似文献/References:

[1]邵毅 周琼 易昀敏 余瑶 裴重刚 吴晓蓉 梅峰 占敏艳.鬼针草叶治疗非增生型糖尿病视网膜病变的临床研究[J].眼科新进展,2013,33(6):000.
[2]李国兴 韩丽英.曲安奈德玻璃体腔注射治疗黄斑水肿[J].眼科新进展,2008,28(9):000.
[3]周正申 孙静芬.白内障超声乳化术后黄斑区光学相干断层扫描观察[J].眼科新进展,2013,33(2):000.
[4]刘广峰 蔺洁 范颖 顾铮 高新晓 朱岩 孟忻 王华 贾宇颂 付秀稳 汪军.非增生型糖尿病视网膜病变黄斑水肿患者黄斑区谱域光学相干断层扫描中高反射信号的特征分析[J].眼科新进展,2013,33(4):000.
[5]鲁丹 王康 王艳玲 林鹏耀 李茜 李明铭.后Tenon囊下注射曲安奈德辅助全视网膜光凝治疗糖尿病视网膜病变[J].眼科新进展,2013,33(5):000.
[6]张祺 冯劼 李培凤 金翼.Lucentis联合氪黄激光治疗视网膜分支静脉阻塞黄斑水肿的疗效观察[J].眼科新进展,2013,33(12):000.
[7]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[8]徐斌 戴奕娟 梁丽 杨露. 传统格栅样激光与577nm黄色微脉冲激光光凝治疗黄斑水肿疗效对比[J].眼科新进展,2014,34(2):181.
[9]陈素芳 曾莉 邵毅. 非诺贝特在糖尿病视网膜病变中的应用进展[J].眼科新进展,2014,34(3):283.
[10]肖昂,周琼.Aflibercept治疗湿性AMD和黄斑水肿的相关研究现状[J].眼科新进展,2014,34(6):598.[doi:10.13389/j.cnki.rao.2014.0165]
[11]滕娟,陈小红,陈梅珠,等.非增生型糖尿病视网膜病变患者黄斑水肿与中心凹下脉络膜厚度的关系[J].眼科新进展,2017,37(3):244.[doi:10.13389/j.cnki.rao.2017.0061]
　TENG Juan,CHEN Xiao-Hong,CHEN Mei-Zhu,et al.Relationship between macular edema and subfoveal choroidal thickness in patients with non proliferative diabetic retinopathy[J].Recent Advances in Ophthalmology,2017,37(4):244.[doi:10.13389/j.cnki.rao.2017.0061]

备注/Memo

备注/Memo:
湖北省卫生计生科研基金资助项目(编号：WJ2015 MB258)；爱尔眼科医院集团科研基金项目(编号：AF141D04)
更新日期/Last Update: 2017-04-26